Home
report store
gastroenteropancreatic neuroendocrine tumors gep nets epidemiology forecast

gastroenteropancreatic-neuroendocrine-tumors-gep-nets-epidemiology-forecast-report

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Epidemiology Forecast - 2036

Published Date : 2025

Pages : 112

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

gastroenteropancreatic neuroendocrine tumors gep nets epidemiology forecast

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Insights and Trends

GEP NETs are heterogeneous tumors arising from neuroendocrine cells in the gastrointestinal tract and pancreas, with incidence increasing over recent decades, partly due to enhanced detection and imaging practices; while exact rates vary by region and subtype, their rising recognition underscores unmet clinical needs.
According to the secondary search, net project, the incidence of malignant GEP-NET during 2000–2007 was 1.7 per 100,000 population per year in Europe, corresponding to an estimated 26,000 new cases.
As per the secondary sesrch, the annual incidence of the disease was 6.47 cases per 100,000 population, with an adjusted prevalence of 0.052%. The mean age at diagnosis was 58 ± 15 years, and the sex distribution was nearly equal, with 51% men and 49% women in Spain.
The most common primary tumor site was the pancreas (52%), followed by the jejunum–ileum (23%).
Non-functional/asymptomatic/unknown NETs are more in number than functional NETs.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Epidemiology Forecast in the US

2025 Incident Cases of GEP-NET: ~19,000
GEP-NET Growth Rate (2026–2036): 2% CAGR

DelveInsight's ‘Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the GEP-NET, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period	2022–2036
Historical Year	2022–2025
Forecast Period	2026–2036
Base Year	2026
Geographies Covered	North America : The US; Europe: Germany, France, Italy, and Spain and the UK; Asia-Pacific: Japan
GEP-NET Epidemiology CAGR (Forecast period) (US)	2% (2026–2036)
GEP-NET Epidemiology Segmentation Analysis	Patient Burden Assessment Total Incident Cases of NET Total Incident Cases of GEP-NET Grade-specific Incident Cases of GEP-NET Functional status Incident Cases of GEP-NET Stage-specific Incident Cases of GEP-NET SSR Positive Incident Cases of GEP-NET Total Treated Cases of GEP-NET

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Understanding and Diagnosis Algorithm

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Overview and Diagnosis

GEP-NET are rare, heterogeneous cancers of the pancreas and gastrointestinal tract. Their complexity and late-stage presentation require individualized treatment based on tumor grade, location, hormone activity, and patient symptoms, with management primarily focused on advanced and metastatic disease. Despite advances in diagnostics, GEP-NET are often not identified for up to 5–7 years after clinical symptoms appear, as the symptoms are not specific.

Further details are provided in the report.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Diagnosis

Diagnosis of GEP-NET relies on a combination of biochemical testing, imaging, and sometimes genetic evaluation. Common biochemical markers include chromogranin A, pancreatic hormones (insulin, gastrin, glucagon), and serotonin metabolites such as 5-HIAA in urine, depending on tumor functionality. Imaging studies such as contrast-enhanced CT and MRI are used to localize primary tumors and assess metastatic spread.

Further details are provided in the report.

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Epidemiology

Key Findings from GEP-NET Epidemiological Analysis and Forecast

According to DelveInsight’s estimates, in 2025, the total number of incident cases of NETs in the US were ~31,000.
At the time of diagnosis, 24% of patients presented with distant metastases, most frequently involving the liver (44%), peritoneum (25%), or multiple organs (22%). The majority of tumors were sporadic and non-functional.
Surgical resection of the primary tumor was performed in 66% of patients. Histopathological grading showed that most tumors were well differentiated, with 73% classified as Grade 1 (G1), 22% as Grade 2 (G2), and 5% as Grade 3 (G3).
The incidence of GEP-NET is higher in the US compared with Germany or France.
The incidence of GEP-NET continues to increase-particularly in older adults.
GEP NETs represent the most common NET subtype, comprising 50–70% of all NETs.

Scope of the Report

The report covers a segment of a descriptive overview of GEP-NET, explaining their causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Patient Population Forecast

Report Key Strengths

Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
11-year Forecast
Patient Burden Trends (by geography)

Unlock comprehensive Gastroenteropancreatic Neuroendocrine Tumors Indication Market Insights with detailed forecasts, epidemiology trends, and emerging therapeutic opportunities through 2036.

FAQs

What are the disease risks, burdens, and unmet needs of GEP-NET? What will be the growth opportunities across the 7MM concerning the patient population with GEP-NET?
What is the historical and forecasted GEP-NET patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Epidemiology Methodology of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

5 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Epidemiology Overview at a Glance

5.1 Patient Share (%) Distribution by Country in 2025 in the 7MM

5.2 Patient Share (%) Distribution by Country in 2036 in the 7MM

6 Disease Background And Overview of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

6.1 Introduction

6.2 Causes

6.3 Signs And Symptoms

6.4 Diagnosis

6.4.1 Differential Diagnosis

6.4.2 Diagnostic Algorithm

6.4.3 Diagnostic Guidelines

6.4.3.1 NCCN Guidelines for Diagnosis of GEP-NET (2025)

6.4.3.1.1 NCCN Guidelines Version 2.2024 Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract (Well-Differentiated Grade 1/2), Lung, and Thymus

6.4.3.1.2 NCCN Guidelines: Well-Differentiated, Grade 3 NETs

6.4.3.1.3 NCCN Guidelines NETs of the Pancreas : Well-differentiated Grade 1/2)

6.4.3.2 European Neuroendocrine Tumor Society (ENETS): Guidance Paper for Gastroduodenal NETs G1–G3

7 Epidemiology and Patient Population of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)

7.1 Key Findings

7.2 Assumption and Rationale

7.3 Total Incident Cases of GEP-NET in the 7MM

7.4 The United States

7.1 Total Incident Cases of NET in the United States

7.4.3 Total Incident Cases of GEP-NET in the United States

7.4.4 Grade-specific Incident Cases of GEP-NET in the United States

7.4.4 Functional status Incident Cases of GEP-NET in the United States

7.4.5 Stage-specific Incident Cases of GEP-NET in the United States

7.4.6 SSR Positive Incident Cases of GEP-NET in the United States

7.4.7 Total Treated Cases of GEP-NET

7.5 EU4 and the UK

7.5.1 Total Incident Cases of NET in EU4 and the UK

7.5.2 Total Incident Cases of GEP-NET in EU4 and the UK

7.5.3 Grade-specific Incident Cases of GEP-NET in EU4 and the UK

7.5.4 Functional status Incident Cases of GEP-NET in EU4 and the UK

7.5.5 Stage-specific Incident Cases of GEP-NET in EU4 and the UK

7.5.6 SSR Positive Incident Cases of GEP-NET in EU4 and the UK

7.5.7 Total Treated Cases of GEP-NET

7.6 Japan

7.6.1 Total Incident Cases of NET in Japan

7.6.2 Total Incident Cases of GEP-NET in Japan

7.6.3 Grade-specific Incident Cases of GEP-NET in Japan

7.6.4 Functional status Incident Cases of GEP-NET in Japan

7.6.5 Stage-specific Incident Cases of GEP-NET in Japan

7.6.6 SSR Positive Incident Cases of GEP-NET in Japan

7.6.7 Total Treated Cases of GEP-NET

8 Appendix

8.1 Bibliography

8.2 Report Methodology

9 DelveInsight Capabilities

10 Disclaimer

11 About DelveInsight

List of Tables:

List of Tables

Table 1: Summary of NET Epidemiology (2022–2036)

Table 2: Summary of GEP-NET Epidemiology (2022–2036)

Table 3: Total Incident Cases of NET in the 7MM (2022–2036)

Table 4: Total Incident Cases of GEP-NET in the 7MM (2022–2036)

Table 5:Total Incident Cases of NET in the United States (2022–2036)

Table 6:Total Incident Cases of GEP-NET in the United States (2022–2036)

Table 7: Grade-specific Incident Cases of GEP-NET in the United States (2022–2036)

Table 8: Functional status Incident Cases of GEP-NET in the United States (2022–2036)

Table 9: Stage-specific Incident Cases of GEP-NET in the United States (2022–2036)

Table 10: SSR Positive Incident Cases of GEP-NET in the United States (2022–2036)

Table 11: Total Treated Cases of GEP-NET in the United States (2022–2036)

Table 12: Total Incident Cases of NET in EU4 and the UK (2022–2036)

Table 13: Total Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Table 14: Grade-specific Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Table 15: Functional status Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Table 16: Stage-specific Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Table 17: SSR Positive Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Table 18: Total Treated Cases of GEP-NET in EU4 and the UK (2022–2036)

Table 19: Total Incident Cases of NET in Japan (2022–2036)

Table 20: Total Incident Cases of GEP-NET in Japan (2022–2036)

Table 21: Grade-specific Incident Cases of GEP-NET in Japan (2022–2036)

Table 22: Functional status Incident Cases of GEP-NET in Japan (2022–2036)

Table 23: Stage-specific Incident Cases of GEP-NET in Japan (2022–2036)

Table 24: SSR Positive Incident Cases of GEP-NET in Japan (2022–2036)

Table 25: Total Treated Cases of GEP-NET in Japan (2022–2036)

List of Figures:

List of Figures

Figure 1: Summary of NET Epidemiology (2022–2036)

Figure 2: Summary of GEP-NET Epidemiology (2022–2036)

Figure 3: Total Incident Cases of NET in the 7MM (2022–2036)

Figure 4: Total Incident Cases of GEP-NET in the 7MM (2022–2036)

Figure 5:Total Incident Cases of NET in the United States (2022–2036)

Figure 6:Total Incident Cases of GEP-NET in the United States (2022–2036)

Figure 7: Grade-specific Incident Cases of GEP-NET in the United States (2022–2036)

Figure 8: Functional status Incident Cases of GEP-NET in the United States (2022–2036)

Figure 9: Stage-specific Incident Cases of GEP-NET in the United States (2022–2036)

Figure 10: SSR Positive Incident Cases of GEP-NET in the United States (2022–2036)

Figure 11: Total Treated Cases of GEP-NET in the United States (2022–2036)

Figure 12: Total Incident Cases of NET in EU4 and the UK (2022–2036)

Figure 13: Total Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Figure 14: Grade-specific Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Figure 15: Functional status Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Figure 16: Stage-specific Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Figure 17: SSR Positive Incident Cases of GEP-NET in EU4 and the UK (2022–2036)

Figure 18: Total Treated Cases of GEP-NET in EU4 and the UK (2022–2036)

Figure 19: Total Incident Cases of NET in Japan (2022–2036)

Figure 20: Total Incident Cases of GEP-NET in Japan (2022–2036)

Figure 21: Grade-specific Incident Cases of GEP-NET in Japan (2022–2036)

Figure 22: Functional status Incident Cases of GEP-NET in Japan (2022–2036)

Figure 23: Stage-specific Incident Cases of GEP-NET in Japan (2022–2036)

Figure 24: SSR Positive Incident Cases of GEP-NET in Japan (2022–2036)

Figure 25: Total Treated Cases of GEP-NET in Japan (2022–2036)

Related Reports

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Pipeline Insight, 2026

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Pipeline Insights, 2026 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) market.

Gastroenteropancreatic Neuroendocrine Tumors Market Insight, Epidemiology And Market Forecast - 2036

DelveInsight's Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding..

License Type

Offer